CLYM Climb Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CLYM matters now
Climb Bio, Inc. (CLYM) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.00 with +1.30% on the session and $954.6M in market capitalization; recent performance reads 1-month +18.65% and YTD +186.25%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.7M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.9%.
The latest indexable market news headline is "Why Is Climb Bio Stock Gaining Friday?" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Dunn Judith filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.27
P/S
0.00
EV/EBITDA
-14.68
DCF Value
$0.49
FCF Yield
-6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-31.5%
ROA
-34.6%
ROIC
-40.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.7M | $-0.20 |
| Q4 2025 | $0.00 | $-17.5M | $-0.26 |
| FY 2025 | $0.00 | $-59.9M | $-0.88 |
| Q3 2025 | $0.00 | $-12.9M | $-0.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.67
Target (Median)
$20.00
Target Range
$17.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.12
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.